No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 36 of the 40 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Achieve Life Sciences, Inc. (ACHV) stock was $7.15 as of Oct 6, 2026, 11:05 AM EDT, up 2.00% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +121.9% · 3-year avg +20.6%/yr · 5-year avg -4.3%/yr
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline.
Biotechnology · Bothell, WA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.20
Revenue Est.
$10.65M
Last Quarter Results
EPS
$-0.80
vs Estimate
$-0.16
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACHV | $734.01M | $7.15 | +2.00% | +121.94% | -4.33% | -39.18% | N/A |
| 2CTKB | $726.43M | $5.63 | -7.64% | +53.09% | -23.16% | N/A | vs ACHV |
| 3AVTX | $725.93M | $13.81 | -5.41% | +8.91% | -70.04% | -48.70% | vs ACHV |
| 4COLL | $713.54M | $22.00 | +0.59% | -36.67% | +2.15% | +1.39% | vs ACHV |
| 5OLMA | $713.19M | $8.16 | -1.03% | -25.57% | -21.50% | N/A | vs ACHV |
| 6CADL | $757.61M | $10.34 | +1.08% | +83.46% | -1.42% | N/A | vs ACHV |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 13 analysts
Average Price Target
$14.15
+98.0% upside
Low
$9.00
Current
$7.15
High
$21.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.22 | $-0.20 | $-0.16 | 8 |
| Quarter ending Dec 2026 | $-0.25 | $-0.21 | $-0.14 | 8 |
| Quarter ending Mar 2027 | $-0.18 | $-0.18 | $-0.18 | 3 |
| Quarter ending Jun 2027 | $-0.15 | $-0.15 | $-0.15 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.56 | $-1.46 | $-1.35 | 8 |
| FY 2027 | $-0.99 | $-0.68 | $-0.24 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $10.65M | $10.65M | $10.65M | 1 |
| Quarter ending Dec 2026 | $17.75M | $17.75M | $17.75M | 1 |
| Quarter ending Mar 2027 | $3.67M | $3.67M | $3.67M | 1 |
| Quarter ending Jun 2027 | $5.95M | $5.95M | $5.95M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.25M | $4.50M | $4.75M | 7 |
| FY 2027 | $8.75M | $35.42M | $53.56M | 9 |
